Gastrointestinal (GI): NSAIDs that block COX-1 activity have correlations with GI issues as a result of inhibition of the synthesis of gastroprotective brokers which include PGE2 as well as other prostaglandins. This inhibition causes decreased mucin creation by gastric epithelial cells, fewer bicarbonate secretion, and less epithelial mobile turnover, among https://anthonyl479cfh6.blogmazing.com/profile